← Leaderboards
Steven Edward Lipshultz
University Of Rochester
$33,670,932
Attributed
$38,898,006
Total exposure
18
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.5M · FY2005–21$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$47,169,017 · 19
By mechanism
R01$39,708,353 · 12
N01$7,400,391 · 1
M01$35,273 · 4
R13$25,000 · 2
Top collaborators
- Eric Jessen Chow5 shared
- Shelley Deanne Miyamoto5 shared
- Carmen C Sucharov5 shared
- Russell Barrett Van Dyke4 shared
- Ling Shi2 shared
Others in their field
Top investigators on “Child”
- Barbara Driver · Westat, Inc.$244,454,458
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$195,214,889
- George R Seage · Abt Associates, Inc.$189,009,744
- Carol Nesel · Westat$188,148,170
- Elizabeth A Thom · George Washington University$170,579,744
Research focus
ChildClinical ResearchChildhoodCardiomyopathiesMyocardium DisorderEchocardiographyCohortDiagnosisVentricularCardiacLeftHeart FailureHuman SubjectFutureChild (0-11)BaseMorbidity - Disease RateMeasurementGenesTransplantationAdultCardiovascular DiseasesHeart TransplantationCardiovascular Disorder Epidemiology
Grant awards (64)
Prognostic Significance of microRNA Expression in Children with Cardiomyopathy$799,064
R01 · FY2021 · HL · contact PI
Prognostic Significance of microRNA Expression in Children with Cardiomyopathy$800,404
R01 · FY2020 · HL · contact PI
Cardiac Toxicity in Perinatally HIV-Infected Adolescents and Young Adults, a Longitudinal Study$672,429
R01 · FY2020 · HL · contact PI
Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy$455,562
R01 · FY2020 · CA
Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy$229,522
R01 · FY2020 · CA
Prognostic Significance of microRNA Expression in Children with Cardiomyopathy$898,361
R01 · FY2019 · HL · contact PI
Cardiac Toxicity in Perinatally HIV-Infected Adolescents and Young Adults, a Longitudinal Study$862,934
R01 · FY2019 · HL · contact PI
Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy$627,308
R01 · FY2019 · CA
Prognostic Significance of microRNA Expression in Children with Cardiomyopathy$795,301
R01 · FY2018 · HL · contact PI
Cardiac Toxicity in Perinatally HIV-infected Adolescents and Young Adults, a Longitudinal Study$729,481
R01 · FY2018 · HL · contact PI
Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy$646,503
R01 · FY2018 · CA
Prognostic Significance of microRNA Expression in Children with Cardiomyopathy$47,571
R01 · FY2018 · HL · contact PI
Cardiac Toxicity in Perinatally HIV-infected Adolescents and Young Adults, a Longitudinal Study$893,037
R01 · FY2017 · HL · contact PI
Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy$742,626
R01 · FY2017 · CA
Genotype-Phenotype Associations in Pediatric Cardiomyopathy$2,092,559
R01 · FY2015 · HL · contact PI
Genotype-Phenotype Associations in Pediatric Cardiomyopathy$2,113,516
R01 · FY2014 · HL · contact PI
Third International Conference on Cardiomyopathy in Children$10,000
R13 · FY2014 · HL · contact PI
Genotype-Phenotype Associations in Pediatric Cardiomyopathy$2,089,535
R01 · FY2013 · HL · contact PI
Cardiac Biomarkers in Pediatric Cardiomyopathy$1,295,072
R01 · FY2013 · HL · contact PI
Cardiac Biomarkers in Pediatric Cardiomyopathy$1,277,688
R01 · FY2013 · HL · contact PI
NATIONAL STANDARD FOR NORMAL FETAL GROWTH - DATA COORD CTR$877,012
N01 · FY2013 · HD · contact PI
Genotype-Phenotype Associations in Pediatric Cardiomyopathy$2,268,513
R01 · FY2012 · HL · contact PI
Cardiac Biomarkers in Pediatric Cardiomyopathy$1,430,582
R01 · FY2012 · HL · contact PI
NATIONAL STANDARD FOR NORMAL FETAL GROWTH - DATA COORD CTR$6,523,379
N01 · FY2011 · HD · contact PI
Pediatric Cardiomyopathy Registry$951,890
R01 · FY2009 · HL · contact PI
Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors$323,497
R01 · FY2009 · CA · contact PI
Pediatric Cardiomyopathy Registry$922,539
R01 · FY2008 · HL · contact PI
HAART Associated Cardiotoxicity in HIV-Infected Children$397,918
R01 · FY2008 · HL · contact PI
Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors$323,497
R01 · FY2008 · CA · contact PI
Pediatric Cardiomyopathy Registry$929,873
R01 · FY2007 · HL · contact PI
HAART Associated Cardiotoxicity in HIV-Infected Children$384,030
R01 · FY2007 · HL · contact PI
Genetic Mechanisms of Anthracycline Cardiotoxicity in Pediatric Cancer Survivors$349,997
R01 · FY2007 · CA · contact PI
Primary Cardiomyopathies in Children: Research Directions & Strategies$15,000
R13 · FY2007 · HL · contact PI
Pediatric Cardiomyopathy Registry$883,515
R01 · FY2006 · HL · contact PI
Cardiovascular Status of HAART-Exposed Infants/Children$620,709
R01 · FY2006 · HL · contact PI
HAART Associated Cardiotoxicity in HIV-Infected Children$391,411
R01 · FY2006 · HL · contact PI
Cardiovascular Status of HAART-Exposed Infants/Children$1,207,409
R01 · FY2005 · HL
Pediatric Cardiomyopathy Registry$928,373
R01 · FY2005 · HL
HAART Associated Cardiotoxicity in HIV-Infected Children$399,329
R01 · FY2005 · HL
Pediatric Cardiomyopathy Biologic Speciment Repository$0
R01 · FY2005 · HL
Functional Status Substudy$0
R01 · FY2005 · HL
Cardiovascular Status of HAART-Exposed Infants/Children$1,247,207
R01 · FY2004 · HL
HAART Associated Cardiotoxicity in HIV-Infected Children$418,135
R01 · FY2004 · HL
Cardiac Status in Long-Term Survivors of Childhood Cancer$15,660
M01 · FY2004 · RR
Cardiovascular Status of HAART-Exposed Infants/Children$849,930
R01 · FY2003 · HL
PEDIATRIC CARDIOMYOPATHY REGISTRY$429,101
R01 · FY2003 · HL
Cardiovascular Status of HAART-Exposed Infants/Children$424,963
R01 · FY2003 · HL
PEDIATRIC CARDIOMYOPATHY REGISTRY$401,294
R01 · FY2003 · HL
Cardiovascular Status of HAART-Exposed Infants/Children$1,280,662
R01 · FY2002 · HL
PEDIATRIC CARDIOMYOPATHY REGISTRY$827,211
R01 · FY2002 · HL
CARDIAC RISK FACTORS IN PEDIATRIC CANCER SURVIVORS$337,486
R01 · FY2002 · CA
CARDIAC RISK FACTORS IN PEDIATRIC CANCER SURVIVORS$26,185
R01 · FY2002 · CA
MYOCARDIAL DAMAGE IN CHILDREN WITH ACUTE ILLNESS$0
M01 · FY2002 · RR
CARDIAC STATUS IN LONG TERM SURVIVORS OF CHILDHOOD CANCER$0
M01 · FY2002 · RR
PEDIATRIC CARDIOMYOPATHY REGISTRY$741,974
R01 · FY2001 · HL
CARDIAC RISK FACTORS IN PEDIATRIC CANCER SURVIVORS$357,204
R01 · FY2001 · CA
MYOCARDIAL DAMAGE IN CHILDREN WITH ACUTE ILLNESS$19,613
M01 · FY2001 · RR
MYOCARDIAL DAMAGE IN CHILDREN WITH PRESUMED VIRAL ILLNESS$0
M01 · FY2001 · RR
PEDIATRIC CARDIOMYOPATHY REGISTRY$801,320
R01 · FY2000 · HL
PEDIATRIC CARDIOMYOPATHY REGISTRY$453,921
R01 · FY2000 · HL
CARDIAC RISK FACTORS IN PEDIATRIC CANCER SURVIVORS$330,205
R01 · FY2000 · CA
CARDIAC STATUS IN LONG TERM SURVIVORS OF CHILDHOOD CANCER$0
M01 · FY2000 · RR
MYOCARDIAL DAMAGE IN CHILDREN WITH PRESUMED VIRAL ILLNESS$0
M01 · FY2000 · RR
MYOCARDIAL DAMAGE IN CHILDREN WITH ACUTE ILLNESS$0
M01 · FY2000 · RR